Cohort 2: GSBR-1290 for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Gasherbrum Bio, Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Summary

This trial is testing a new capsule called GSBR-1290 to see if it is safe and well-tolerated when taken by mouth. The study involves healthy adult participants from both Japanese and non-Japanese backgrounds. Researchers will give different doses over a period of time to compare the effects between these groups.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups

Experimental Treatment

Group I: Cohort 2: GSBR-1290Experimental Treatment1 Intervention

Healthy non-Japanese participants (Caucasians or African Americans) will receive once daily doses of study drug (GSBR-1290 oral capsules) for up to 4 weeks.

Group II: Cohort 1: GSBR-1290 or PlaceboExperimental Treatment2 Interventions

Healthy Japanese participants will receive once daily doses of study drug (GSBR-1290 or placebo oral capsules) for up to 4 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

GSBR-1290

2023

Completed Phase 2

~160

Do I qualify?Apply below to find out